HCP Live
Contagion LiveCGT LiveNeurology LiveHCP LiveOncology LiveContemporary PediatricsContemporary OBGYNEndocrinology NetworkPractical CardiologyRheumatology Netowrk

NeurologyLive® Top Expert Interviews: September 2022

Expert clinicians offer their perspectives on developmental milestones for children, the NMSOD patient perspective, effective treatments for insomnia, ALS, diabetic and inflammatory neuropathies, and lecanemab in early Alzheimer disease.

The NeurologyLive® team has been as busy as ever collecting expert insight on the latest clinical news and research updates in neurology over the course of the past month by conducting several interviews across various topics of neurological care.

Among these included conversations about the changes in practice and developmental milestones for children, the patient perspective on neuromyelitis optica spectrum disorder (NMSOD), the state of insomnia and the effective treatment strategies, the role of human endogenous retroviruses in amyotrophic lateral sclerosis (ALS), the changing treatment of diabetic and inflammatory neuropathies, and lecanemab’s effect in early Alzheimer disease (AD).

Click through the slides to see and read more from each expert’s exclusive conversation with NeurologyLive® in September 2022.

To hear more insight from experts in the clinical care of patients and leading researchers in neurology, check out more of NeurologyLive®'s videos.

REFERENCES
1. Zubler JM, Wiggins LD, Macias MM, et al. Evidence-informed milestones for developmental surveillance tools. Pediatrics. 2022;149(3):e2021052138. doi:10/1542/peds.2021-052138
2. Steiner JP, Bachani M, Malik N, et al. Human endogenous retrovirus K envelop in spinal fluid of amyotrophic lateral sclerosis. Annals of Neurol. Published July 8, 2022. doi:10.1002/ana.26452
3. Garcia-Montojo M, Simula ER, Fathi S, et al. antibody response to HML-2 may be protective in amyotrophic lateral sclerosis. Annals of Neurol. Published online July 31, 2022. doi:10.1002/ana.26466
4. Lecanemab confirmatory phase 3 clarity ad study met primary endpoint, showing highly statistically significant reduction of clinical decline in large global clinical study of 1,795 participants with early Alzheimer’s disease. News release. Eisai, Biogen. September 27, 2022. Accessed October 6, 2022. https://www.prnewswire.com/news-releases/lecanemab-confirmatory-phase-3-clarity-ad-study-met-primary-endpoint-showing-highly-statistically-significant-reduction-of-clinical-decline-in-large-global-clinical-study-of-1-795-participants-with-early-alzheimers-disease-301634888.html